Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341484 · ClinicalTrials.gov registry record
Genetic Susceptibility to Oncogenic Viruses
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,580
- Enrollment target
NCT00341484: Completed study, sponsored by National Cancer Institute (NCI).
NCT00341484 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,580 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00341484 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,580 participants
- Enrollment target
Study Summary
An NCI goal is to identify every human gene that predisposes people to cancer. Recent studies of HIV-1 indicate that genetic polymorphisms can affect susceptibility to viral infections and that such alleles may be racially restricted, a range of racial and ethnic groups should be included in such studies. We propose to examine genetic determinants of infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in an ethnically diverse population of injection drug users (IDUs). HBV and HCV are important causes of hepatocellular carcinoma, but little is known about genetic factors that alter susceptibility to these infections. Subjects will be recruited in diverse inner-city neighborhoods as part of the University of California, San Francisco's Urban Health Study. Since 1986, this study has successfully recruited and evaluated IDUs from street-based settings. About half of the participants are African-American, one-third are white, 10% are Latino, and the remainder are Asian or Native American. The mean duration of drug use exceeds 20 years. About 80% of subjects have evidence of HBV infection and a similar prevalence of HCV infections is anticipated. We will enroll about 1500 subjects over a 13 month period. Archived, unlinked serum specimens may be obtained from previous enrollees to increase the sample size, as needed. Highly exposed-uninfected subjects will be ascertained on the basis of the serologic testing for each virus, as well as the duration and frequency of injection drug use. These highly exposed-uninfected subjects will be compared to infected subjects with regard to their frequency of genetic polymorphisms (chemokines, chemokine receptors, human leukocyte antigens, and others), in collaboration with scientists from NCI's Laboratory of Genomic Diversity.
Primary Outcome
genetic determinants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,580 participants |
| Start Date | 1998-06-01 |
| Est. Completion | 2007-06-05 |
What the finished NCT00341484 record still lists
NCT00341484 is an observational study that tracks outcomes without assigning an intervention. Its 2,580 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00341484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00341484 about?
NCT00341484 is a clinical study titled "Genetic Susceptibility to Oncogenic Viruses". An NCI goal is to identify every human gene that predisposes people to cancer. Recent studies of HIV-1 indicate that genetic polymorphisms can affect susceptibility to viral infections and that such alleles may be racially restricted, a range of racial and ethnic groups should be included in such st...
What is the current status of trial NCT00341484?
This trial is currently completed. The enrollment target is 2,580 participants. The study started on 1998-06-01. Estimated completion is 2007-06-05.
Who is sponsoring clinical trial NCT00341484?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI